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Overview
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Outline & Goals
• Background – What are “LUTS”?
• Anatomy
• Pathophysiology
• Storage – bladder filling symptoms
• Voiding – urine flow symptoms
• Post-micturition
• Major etiologies and management
• BPH / BOO
• OAB
• Nocturia
• Related to Prostate Cancer?
What are “LUTS”
• Non-specific!
• Any combination of urinary symptoms or
• Symptoms primarily associated with overactive bladder 
(frequency, urgency, and nocturia) 
• International Consensus Conference (2005) defined LUTS to 
include symptoms relating to storage and/or voiding 
disturbances common among aging men
• So, the more detail you get, the better you can identify the 
problem!
Epidemiology
Rancho Bernardo study – prospective administration of AUA Symptom Index (0-35 points)
• 60% of the entire cohort had LUTS – but increased significantly with each decade age
Parson JK et al. Urology 2008.
Aging Population
• The number of 
Americans ages 65 and 
older will more than 
double over the next 
40 years, reaching 80 
million in 2040. 
• The number of adults 
ages 85 and older, the 
group most often 
needing help with 
basic personal care, 
will nearly quadruple 
between 2000 and 
2040.
Aging Population
MALE GENITOURINARY ANATOMY
ANATOMY
Sphincter mechanism
ANATOMY
Pathophysiology of LUTS
Pathophysiology of LUTS

Etiologies of LUTS
BPH & BOO
First, we need to define these terms:
• Benign Prostatic Hyperplasia (BPH)
• Histologic diagnosis
• stromoglandular hyperplasia
• Benign prostatic enlargement (BPE)
• Anatomic enlargement of the gland
• Bladder Outlet Obstruction (BOO)
• Actual manifestation of symptoms
• Pathophysiologic 
• Obstruction of the urethra & 
compromise of urinary flow
BPH-Mass Effect
BPH
Age(yrs) Prevalence
25-30 10%
60 >50%
85 90%
At age 55, 25% of men will have a decrease in the force of 
stream
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BPE & BOO
• Size doesn’t always matter!
The size of the gland does not necessarily predict symptom severity. Some 
men with minimally enlarged prostate glands experience many symptoms 
while other men with much larger glands have few symptoms.
What Are the Symptoms of BPH?
What Are the Symptoms of BPH?
BPH – Long-term Complications
• Silent BPH
• Urinary retention
• UTI
• Bladder stones
• Bladder decompensation
• Renal insufficiency
• Hematuria
Bladder Changes from BPH
• Detrusor instability
• Decreased compliance 
(frequency and urgency)
• Impaired detrusor contractility
• Trabeculation (increase in 
detrusor collagen)
• Diverticulum
AUA Symptom Score Index
Seven questions (0-5):
• Incomplete 
emptying
• Frequency
• Hesitancy
• Urgency
• Weak stream
• Strained voiding
• Nocturia
AUA Symptom Score Index
Mild 0-7
Moderate 8-19
Severe 20-35
* Moderate to severe symptoms are 3.5X higher in men with 
>50 ml prostate 
BPH – Diagnosis & Evaluation
• Detailed history (hematuria, UTI, Diabetes, Neurolgic
Disease, h/o urethral strictures, urinary retention, 
aggravation of symptoms with cold meds)
• Physical Exam: DRE and focused neurologic exam
• AUA Symptom Score Index
• U/A
• ? Serum Creatinine
• PSA
Diagnosis-Additional Tests
• Urinary flow rate
• Post-void residual (Bladder scan)
• Pressure-Flow studies
• Urethrocystoscopy - indicated for planned invasive therapy, 
hematuria, strict disease, previous surgery
• Radiologic imaging – Transrectal / Transabdominal U/S or IVU
BPH - Treatment
• In 1990 - 335,000 surgical procedures for BPH
• TURP was the most common procedure
• Medical therapy and minimally invasive techniques have 
decrease the number of surgical intervention
• 25% of men by age of 80 will undergo treatment
• Cost issue
BPH - Treatment
• Watchful waiting
• Medical Therapy
• Minimally Invasive Techniques- Prostatic Urethral Lifts 
and Steam Thermotherapy
• Surgical Therapy
BPH – Treatment Trends
Advantages
• No surgery
• No drugs
• No side effects
Disadvantages
• No improvement in symptoms
• Risk that symptoms or 
obstruction will worsen
BPH Treatment - ”Watchful Waiting
BPH - Medical Therapy
• First line of treatment for LUTS secondary to BPH
• Alpha blockers
• Low dose Tadalafil (Cialis)
• Androgen Suppression
• Phytotherapy
Medical Therapy - Alpha Blockers
• Non selective Phenoxybenzamine, alfuzosin (IR),Indoramin
• Long acting- terazosin, doxasosin, alfuzosin SR, Silodosin
• Subtype selective- tamsulosin
Medical Therapy - Distribution of alpha-receptors
Medical Therapy - Alpha blockers
• Multicenter, randomized, double-blind, placebo controlled 
studies have demonstrated safety and efficacy
• Rapid and dose dependent
• Durable
Medical Therapy - Androgen Suppression
• GnRH Analogs- Leuprolide, Nafarelin, Cetrorelix
• Progestational Agents-Megestrol, 17 alpha-Hydrocortisone
• Antiandrogens-flutamide, biculatamide, oxandolone, 
zanoterone
• 5 alpha reductase inhibitors (5ARIs)
• Finasteride (Proscar)
• Dutasteride (Avodart)
Medical Therapy – 5ARI’s
• Safety and efficacy has been established 
• Durable
• Reduces prostate size by 20%
• ? Preventive for prostate cancer
Advantages
• No surgery
• Potential for full symptom 
resolution
Disadvantages
• Lifelong commitment
• Side effects
• Effectiveness of drugs lessens over 
time
• Ongoing out-of-pocket costs
Treatment Option – Medical Management
BOO 2/2 BPH – Surgical Treatment
Office Based - Minimally Invasive Therapies 
(MIT)
■ Prostatic Urethral Lift – UroLift
■ Steam Thermotherapy - Rezum
Operating Room - Minimally Invasive 
Treatment Options
• Laser - TULIP, VLAP, 
contact laser
• Laser - Holmium Laser 
Prostatectomy (HoLEP) à
• TURP
Surgical Therapy
• TURP - Holmium Laser 
Prostatectomy (as discussed)
• Open Prostatectomy ààà
• Minimally Invasive Techniques 
(Robotic) à
BPH - Surgical Therapy – Take Home Points
• TURP is still considered gold standard 
• Open/Robotic Prostatectomy is indicated in patients where 
prostate glands are greater than 75-80 grams
• Holmium Laser Prostatectomy is an alternative to TURP
• No size limit in the AUA guidelines
• Only MIT that has no size limit
Treatment Option- Surgery
Advantages
• Proven approach
• Durable response
• Can allow patients to be off 
medications
Disadvantages
• Requires hospitalization
• Requires general anesthesia
• Side effects can be significant
Surgical Indications
• Recurrent UTIs
• Gross Hematuria
• Bladder calculi
• Renal insufficiency
• Urinary Retention
• Bladder Diverticulum
BOO – Causes other than BPH
• Urethral Strictures
• Primary bladder neck obstruction
• Bladder neck contracture
• Detrusor-sphincter dyssynergia
• Prostate cancer – late stage prostate cancer
• Meatal stenosis (circumcised men)
Overactive Bladder (OAB)
• Definition: “urinary urgency, with or without urgency urinary 
incontinence (involuntary loss of urine), in the absence of 
urinary tract infection or other obvious pathology.”
• It is a clinical diagnosis
• Characterized by STORAGE symptoms – and ideally absence 
of VOIDING/obstruction symptom
OAB - Epidemiology
Women > Men
But… 
Still a problem in men!
Overactive Bladder (OAB) - Presentation
Overactive Bladder 
(OAB) – Evaluation
• History (detailed)
• Neurogenic bladder
• Pelvic floor dysfxn
• UTI’s recurrent
• BOO
• Bladder Ca 
(hematuria)
• Physical exam
• Urinalysis/Ucx (if 
indicated)
• Postvoid residual (PVR)
• Symptom questionnaire 
/ bladder diary
Overactive Bladder (OAB) – Secondary to BOO
Overactive Bladder (OAB) – Treatment Paradigm
Overactive Bladder (OAB) – Treatment Paradigm
OAB Treatment - Pathophysiology
Anticholinergics
• Block parasympathetic 
innervation of detrusor 
muscle
Beta-3 Agonist
• Activates relaxation of 
detrusor smooth muscle
Overactive Bladder (OAB) – Medical Management
Overactive Bladder (OAB) – Anticholinergics
Overactive Bladder (OAB) – Beta-3 agonist
OAB Medication 
Summary
• Clinicians should offer oral 
antimuscarinics or oral β3-
adrenoceptor
• ER preferred over IR
• If one anti-muscarinic 
ineffective, then dose 
modification, different 
anti-muscarinic or a β3-
agonist
• Can combine modalities 
for pts refractory to 
monotherapy
Overactive Bladder (OAB) – Surgical Treatments
Nocturia
• Definition: defined as the need to awaken ≥1 times per night 
to void
• Why talk about this separately?
• Long been considered one of a range of symptoms associated 
with LUTS – including BOO and OAB. 
• Although nocturia is urinary frequency that occurs during 
nighttime sleep, it is not necessarily driven by a lower urinary 
tract dysfunction
• It may be driven instead by nighttime urine overproduction, or 
nocturnal polyuria (NP), resulting from renal, cardiovascular, or 
pulmonary factors
Nocturia – Non-Urologic Causes
Nocturia – Obstructive 
Sleep Apnea
Nocturia – Conservative Treatment Rec’s
Nocturia – Medical Management
FIRST LINE THERAPY - Anticholinergic medication
If this first line drug therapy is considered ineffective, one or more of the following 
may be prescribed:
1) Desmopressin - By mimicking ADH or vasopressin, the kidney produces less urine.
2) Imipramine - This medication boasts a 40% success rate but also has a fine line 
between an effective dose and toxic dose.
3) Furosemide - This loop diuretic helps regulate urine production in the daytime in 
order to decrease urine production during sleep. Furosemide blocks ion flow in 
the kidneys, allowing urine production to be more controlled.
4) Bumetanide - This loop diuretic assists in regulating urine production prior to 
sleep so waking during the nighttime does not occur. Bumetanide must be taken 
with caution and consultation with a healthcare professional prior to taking this 
medication is highly recommended.
Nocturia –
Medical 
Management
How does this relate to Prostate Cancer?
Prostate Anatomy
• Prostate Cancer and 
BPH occur in 
different regions of 
the prostate
• PCa rarely causes 
urinary symptoms… 
unless it is quite 
advanced.
PSA

